Lotz Christopher L. 4

4 · Qualigen Therapeutics, Inc. · Filed May 27, 2020

Form 4

Period: 2020-05-22

VP of Finance, CFO.

Transactions

Other
Warrant (Right to Buy)
2020-05-22+3,543→ 3,543 total
Exercise: $2.54From: 2020-05-22Exp: 2026-09-22→ Common Stock (3,543 underlying)
Other
Common Stock
2020-05-22+9,841→ 9,841 total
Other
Warrant (Right to Buy)
2020-05-22+22,142→ 22,142 total
Exercise: $2.07From: 2020-05-22Exp: 2024-01-31→ Common Stock (22,142 underlying)
Other
Warrant (Right to Buy)
2020-05-22+29,847→ 29,847 total
Exercise: $2.07From: 2020-05-22Exp: 2024-08-02→ Common Stock (29,847 underlying)
Other
Warrant (Right to Buy)
2020-05-22+22,142→ 22,142 total
Exercise: $2.54From: 2020-05-22Exp: 2025-03-02→ Common Stock (22,142 underlying)

Footnotes (3)

[F1]On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.
[F2]Immediately prior to the Closing, the Reporting Person was a stockholder of Qualigen. Pursuant to the Merger, the shares of Qualigen common stock previously held by the Reporting Person were converted into 9,841 shares of common stock of the Issuer.
[F3]Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Documents

1 file